<DOC>
	<DOCNO>NCT00273624</DOCNO>
	<brief_summary>60 patient major depression treat 10 mg Olanzapine Placebo 2 week . In case response ( reduction depressive symptom ) study continue 60 day .</brief_summary>
	<brief_title>Olanzapine Augmentation Therapy Treatment-resistant Depression : Double-blind Placebo-controlled Trial</brief_title>
	<detailed_description>The study use randomize double-blind , parallel-group , placebo-controlled design . 30 patient per treatment group include study randomize treatment group use computer program . Psychotic feature depression exclude score 2 less PANSS subscales P1 , P3 P6 . Treatment resistance define history non-response two antidepressant different class acceptable dose period confirm retrospectively . If possible , treatment compliance confirm plasma level examination . After informed consent , visit 1 perform day 0 ( inclusion criterion , history , demographic , physical examination , vital sign , HAMD , MADRS , CGI , lab ) . Study medication start day 1 , antidepressive therapy continue stable dose end study . Patients receive double-blind therapy either 10 mg/d olanzapine placebo . Study visit perform day 4 , 7 , 14 ( visit 2-4 : vital sign , HAMD , MADRS , CGI , lab ) . After 14 day , patient classify responder non-responders . A responder define reduction initial HAM-D score 50 % . Study treatment stop non-responders continue double-blind manner responder 60 day . Thereafter , study medication stop patient observe 14 day . Study visit perform every 14 day . This extension phase add examine prolong treatment olanzapine could ensure sustain treatment effect . It exclude olanzapine short-term tranquillizer-like effect lead unfavourable medium- to-long-term depressiogenic effect observe neuroleptic use depression ( e.g . fluspirilene ) . Moreover , withdrawal effect exclude .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>major depression without psychotic feature therapy resistance ( 2 course antidepressant different class 3 week adequate dose HAMD score greater/equal 17 age 1865 bipolar disorder active alcohol illicit drug use female ineffective contraception severe medical condition , epilepsy psychotic feature</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Therapy-resistant depression</keyword>
	<keyword>add-on therapy depression</keyword>
</DOC>